Piper Jaffray Cut Price Target on F5 Networks (FFIV) Following 1Q Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- Citi initiates UiPath coverage with Buy rating and $23 target
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Alibaba (BABA) PT Lowered to $165 at Bernstein SocGen Group
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Citi Upgrades F5 Networks (FFIV) to Neutral
January 21, 2016 7:11 AM ESTCiti upgraded F5 Networks (NASDAQ: FFIV) from Sell to Neutral.
For an analyst ratings summary and ratings history on F5 Networks click here. For more ratings news on F5 Networks click here.
Shares of F5 Networks closed at $90.02 yesterday.
... MoreBMO Capital Remains Sidelined After F5 Networks (FFIV) Reports 1Q Beat
January 21, 2016 7:04 AM ESTBMO Capital maintained a Market Perform rating on F5 Networks (NASDAQ: FFIV), and cut the price target to $93.00 (from $108.00), following the company's 1Q earnings report. Revenues and EPS of $489M and $1.73, came in above consensus estimates of $486M and $1.60. However, BMO remains concerned that the weak product sales could last longer than expected as new network architectures may be muting demand and... More
After-Hours Stock Movers 01/20: (ECYT) (XLNX) (FEYE) Higher; (OGXI) (SLM) (SRPT) Lower (more...)
January 20, 2016 5:51 PM ESTOncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) 41.8% LOWER; announced that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit. A potential PFS benefit was observed in patients with high baseline serum Hsp27 status when treated with apatorsen. The study is ongoing and overall survival results are expected in the second half of 2016.
Endocyte, Inc. (NASDAQ:... More
F5 Networks (FFIV) Tops Q1 EPS by 13c; Issues Light Q2 Outlook
January 20, 2016 4:06 PM ESTF5 Networks (NASDAQ: FFIV) reported Q1 EPS of $1.73, $0.13 better than the analyst estimate of $1.60. Revenue for the quarter came in at $489.5 million versus the consensus estimate of $485.51 million.
GUIDANCE:
F5 Networks sees Q2 2016 EPS of $1.61-$1.64, versus the consensus of... More
Trading Radar for 1/20: Goldman Sachs (GS), F5 Networks (FFIV), Sallie Mae (SLM), Brinker (EAT) Report
January 19, 2016 2:10 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
7:00am EST
8:30am EST
CPI - Street sees 0.0%Core CPI - Street sees 0.2%Housing Starts - Street sees 1.197MBUilding Permits - Street sees... More